Zydus receives EIR for the transdermal manufacturing facility

Zydus Lifesciences Ltd has received the EIR report from the USFDA for the inspection conducted at its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated (VAI).

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 1080.60 as compared to the previous close of Rs. 1068.35. The total number of shares traded during the day was 13178 in over 1498 trades.

The stock hit an intraday high of Rs. 1083.70 and intraday low of 1063.00. The net turnover during the day was Rs. 14141946.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA EIRReport Pharmex Ahmedabad TransdermalPatchManufacturingFacility